Ryan D Otte

USPTO Granted Patents = 26 (Patent Applications = 5)

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 18 (Patent Applications = 20)

Average Co-Inventor Count = 11.6

ph-index = 7

Forward Citations = 143(Granted Patents)

Location History:

Newton Centre, MA (US) (2009 - 2013)
Natick, MA (US) (2013 - 2023)

Company Filing History:

25 out of 2,405

Merck Sharp + Dohme Corp.

where one patent can have more than one assignee

Years Active: 2009-2025

Loading Chart...

26 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12297208 - Small molecule inhibitors of KRAS G12C mutant (2025-05-13),

2. 12291538 - Small molecule inhibitors of KRAS G12C mutant (2025-05-06),

3. 11702430 - Aza-benzothiophene compounds as STING agonists (2023-07-18),

4. 11697657 - Small molecule inhibitors of KRAS G12C mutant (2023-07-11),

5. 11453697 - Cyclic di-nucleotide compounds as sting agonists (2022-09-27),

6. 10793557 - Sting agonist compounds (2020-10-06),

7. 10766919 - Cyclic di-nucleotide compounds as sting agonists (2020-09-08),

8. 10759825 - Cyclic di-nucleotide compounds as STING agonists (2020-09-01),

9. 10738074 - Cyclic di-nucleotide compounds as STING agonists (2020-08-11),

10. 10730849 - Benzo[b]thiophene compounds as STING agonists (2020-08-04),

11. 10703738 - Benzo[b]thiophene compounds as STING agonists (2020-07-07),

12. 10442819 - Tricyclic compounds as inhibitors of mutant IDH enzymes (2019-10-15),

13. 10414747 - Benzo[b]thiophene compounds as sting agonists (2019-09-17),

14. 9822107 - Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors (2017-11-21),

15. 9775839 - 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors (2017-10-03),

Title: Ryan D Otte: Innovator in Pharmaceutical Chemistry

Introduction: Ryan D Otte, based in Natick, MA, is a prolific inventor in the field of pharmaceutical chemistry with an impressive portfolio of 24 patents. His work has significantly advanced therapeutic approaches, particularly in oncology and immune response modulation.

Latest Patents: Among his latest innovations are two noteworthy patents. The first, titled "Aza-benzothiophene compounds as STING agonists," focuses on compounds that serve as inducers of type I interferon production. These compounds, characterized by a specific general formula, demonstrate utility as STING-active agents capable of inducing immune responses, specifically for treating cell proliferation disorders like cancer. The second patent involves "Small molecule inhibitors of KRAS G12C mutant," which provides compounds that inhibit the KRAS G12C mutant protein, also with a focus on treating cancer. Both patents encompass compositions and methods for synthesizing these compounds, showcasing Ryan's commitment to addressing critical health challenges.

Career Highlights: Ryan D Otte has contributed to major pharmaceutical companies, including Merck Sharp & Dohme Corporation and Merck Canada Inc. His extensive experience in these organizations has enabled him to develop groundbreaking therapeutic solutions that address cancer and related disorders.

Collaborations: Throughout his career, Ryan has worked alongside talented individuals like Michael D Altman and Andrew M Haidle. These collaborations highlight the innovative environment in which he operates, fostering advancements in medicine.

Conclusion: Ryan D Otte stands out as a significant figure in pharmaceutical innovation, with a prolific record of patents and collaborations. His contributions not only enhance the understanding of complex diseases but also hold the potential for transformative treatments in the medical field.

This text is generated by artificial intelligence and may not be accurate.